Ferring International Center SA - Company Profile
Powered by 
All the data and insights you need on Ferring International Center SA in one report.
$295
- Save hours of research time and resources with
our up-to-date Ferring International Center SA Strategy Report
- Understand Ferring International Center SA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Ferring International Center SA (Ferring), a subsidiary of Ferring Holding SA, is a research-driven, specialty biopharmaceutical company. Its primary activities include research and development in reproductive medicine, women's health, gastroenterology and urology. Ferring's product portfolio includes treatments for reproductive medicine and maternal health, gastroenterology and microbiome, urology and uro-oncology, endocrinology, and orthopedics. Ferring's products are used by patients seeking treatments in the areas of reproductive health, gastroenterology, and urology, among others. The company has a global presence with manufacturing sites and R&D centers in countries such as China, Denmark, Brazil, Israel, Japan, India, the UK, and the US. Ferring Pharmaceuticals is headquartered in Saint-Prex, Switzerland.
Headquarters
Switzerland
Address
Ch. de la Vergognausaz 50, Saint-Prex, Waadt, 1162
Website
www.ferring.com
Telephone
41 58 3010000
No of Employees
7,000
Industry
Pharmaceuticals and Healthcare
Ferring International Center SA premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Gastroenterology & Microbiome | Late-Stage Collaborations | Menopur |
| Urology & Uro-Oncology | Drug Discovery Partnering | Endometrin/ Lutinus |
| Endocrinology | Carbetocin Ferring | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | New Products/Services | In January, the company announced the launch of ADSTILADRIN in the US. |
| 2023 | Contracts/Agreements | In December, the company entered into an agreement with PharmaBiome to advance innovative microbiome-based biological therapies in gastrointestinal. |
| 2023 | Contracts/Agreements | In August, the company entered into an agreement with Royalty Pharma for new intravesical gene therapy Adstiladrin (nadofaragene firadenovec-vncg). |
Competitor Comparison
| Key Parameters | Ferring International Center SA | Max Zeller Soehne AG | Med Discovery SA | Mepha Pharma AG | Release Therapeutics |
|---|---|---|---|---|---|
| Headquarters | Switzerland | Switzerland | Switzerland | Switzerland | Switzerland |
| City | Saint-Prex | Romanshorn | Epalinges | Basel | Genève |
| State/Province | Waadt | Thurgau | - | Basel-Stadt | - |
| No. of Employees | 7,000 | 142 | - | 190 | - |
| Entity Type | Private | Private | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jean-Frederic Paulsen | Chairman | Executive Board | 2023 | - |
| Lars Rebien Sorensen | Vice Chairman | Executive Board | 2023 | - |
| Dominic Moorhead | Executive Vice President; Chief Financial Officer | Senior Management | 2017 | - |
| Curt McDaniel | Chief Legal Officer; Secretary - Board | Senior Management | 2020 | - |
| Christelle Beneteau | Senior Vice President; Chief People Officer | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer